The Pathopysiology of Asthma

What happens in the body to give rise to symptoms

Table of Contents
View All
Table of Contents

The pathophysiology of asthma—that is, the processes it entails—involves multiple organs, systems, and mechanisms. While these differ somewhat from one type of asthma to the next, the end result is the same: bronchoconstriction, inflammation, and mucus overproduction that make it harder for you to breathe. What sets all of this into motion, asthma's pathogenesis, is equally complex.

Learning more about how asthma comes about can help you better understand how various treatments and management approaches can minimize asthma's impact on your life and why your healthcare provider recommends certain medications.

Pathophysiology of Asthma

Pathophysiology is the way in which a disease alters the normal function of your body. The term is derived from Greek prefix pathos, meaning "suffering," and the root physiologia, meaning "natural philosophy."

The pathophysiology of asthma involves:

  • Hypersensitivity
  • Hyperresponsiveness to stimuli
  • Bronchoconstriction and inflammation
  • In severe cases, airway remodeling


People with asthma are known to be hypersensitive to things called triggers. What this means is that the immune system incorrectly perceives certain stimuli, such as dust or pollen, to be harmful. This sensitivity is what causes allergies and sensitivities.

Common allergens include:

Common sensitivities include:

Hyperresponsiveness to Stimuli

In asthma, the airways narrow after an irritant is breathed in. This is called hyperresponsiveness, and it's somewhat like a twitch in your airways that's especially easy to induce.

The narrowing of the airways makes it more difficult to breathe. When you use your rescue inhaler, you feel better because the medication relaxes your airways and makes them larger so that air can flow more easily.

Hyperresponsiveness occurs soon after exposure to an allergen and is the first part of an asthma attack. Changes that occur later that have more to do with inflammation.

Bronchoconstriction and Inflammation

Hyperresponsiveness causes your bronchial tubes to contract. At the same time, inflammatory cells and chemicals flood your airways and cause inflammation, which further restricts your breathing and can become chronic.

Bronchoconstriction and inflammation combine with excess production of mucus, which exacerbates breathing difficulty and leads to a chronic cough that works to release the mucus.

Bronchospasm typically lasts for one to two hours before resolving. In some cases, however, it may appear to resolve only to have an attack occur up to 12 hours later.

Asthma symptoms may be present only on occasion or all the time, depending on your asthma severity. Asthma exacerbations involve a more extreme tightening of the airways that makes it hard to breathe and can be life-threatening.

Airway Remodeling

In more severe cases, chronic inflammation can lead to a process called airway remodeling in which the walls of the air passages thicken and harden, the glands enlarge, and networks of blood vessels grow rapidly and abnormally.

While less severe asthma is considered reversible with proper treatment and management, airway remodeling is currently irreversible. It's associated with worsened symptoms and more frequent and severe asthma attacks.

Asthma Doctor Discussion Guide

Get our printable guide for your next healthcare provider's appointment to help you ask the right questions.

Doctor Discussion Guide Old Man

Pathogenesis of Asthma

Taking a step back, all of this begins with a changes that occur at the cellular level.

Hypersensitivity prompts an activation of the immune system and starts a complex chain reaction involving numerous cells and substances. This includes an early phase and a late phase.

The early phase begins when your immune system detects allergens or irritants in your body. In response, plasma cells release an antibody called immunoglobulin E (IgE). Antibodies are specialized cells that attack and try to destroy things your body perceives as threats.

The IgE then attaches itself to several types of white blood cells, which can vary due to the type of asthma.

Mast Cells

Mast cells are especially prevalent in certain areas of your body, including the lungs.

Once IgE attaches to a mast cell, that cell will respond to the presence of an allergen by releasing:

  • Cytokines: Proteins that drive inflammatory processes through interferons, interleukins, and tumor necrosis factor-alpha (TNF-α)
  • Histamine: A chemical messenger that dilates blood vessels, drives inflammation, causes symptoms of an allergic reaction (itchy, watery eyes and sore throat), and leads to bronchoconstriction and mucus production
  • Prostaglandins: A compound involved in inflammation, mucus production, bronchoconstriction, and airway remodeling
  • Leukotrienes: Chemicals that include highly potent bronchoconstrictors
  • Platelet-activating factor (PAF): A substance tied to anaphylaxis, which is a severe and potentially life-threatening allergic reaction, and that may reduce the effectiveness of allergy medications


Basophils perform a number of important functions, perhaps the most important of which is in certain inflammatory reactions, particularly those involving allergies.

Basophils are a part of the innate immune system, which triggers a non-specific reaction to anything the body considers harmful. Unlike adaptive immunity, which elicits a targeted response, innate immunity results in a generalized attack that involves inflammation, swelling, pain, fever, and fatigue.

Basophils, like mast cells, produce histamine, leukotrienes, and PAF. Having too many basophils in your blood (basophilia) can be a powerful driver of asthma symptoms, including:

  • Severe inflammation of the lungs
  • Bronchoconstriction
  • Excessive production of mucus, causing coughing and respiratory obstruction

Basophils are especially implicated in allergic asthma.


Eosinophils are less involved in allergic asthma and associated more with their own subtype, called eosinophilic asthma (e-asthma).

E-asthma is often severe and comes on most often in adulthood. While it involves an allergic response, many people with this type of asthma don't actually have allergies.


  • Contain inflammatory chemicals
  • Create leukotrienes (which increase bronchoconstriction)
  • Express numerous cytokines (which drive inflammation)

E-asthma is believed to be associated with a set of symptoms not present with other asthma types, including:

When chronic rhinosinusitis and nasal polyps accompany asthma, they can predispose you to aspirin-induced asthma. When all three conditions are present, they are collectively known as Samter's Triad.


People with severe asthma that doesn't respond well to treatment with corticosteroid medications often have high levels of neutrophils. Their condition is sometimes referred to as neutrophilic asthma.

Produced in the bone marrow, neutrophils are first-line responders. They destroy allergens and other invading organisms (viruses, bacteria) by surrounding and ingesting them.

Neutrophils are part of an acute inflammatory response. They:

  • Activate and regulate several immune cells
  • Support chronic inflammation
  • Release an array of cytokines and PAF
  • Release thromboxane, a hormone that constricts the smooth muscles of the airways

They're involved in both the innate and adaptive immune response as well.

T Helper 2 Cells

T helper 2 (Th2) cells do as their name suggests: They support other cells in several ways, including assisting with their activation. Of course, in asthma, these key players in the immune response are what help trigger asthma symptoms:

  • GM-CSF: This cytokine tells stem cells to produce basophils, eosinophils, and neutrophils, which help sustain inflammation.
  • Interleukins: These immune-response regulators help keep basophils and eosinophils alive; one of them contributes to airway remodeling and thickening.


Like neutrophils, macrophages are made in your bone marrow and engulf foreign substances to destroy them. In asthma, macrophages release substances that initiate and prolong hyperresponsiveness of the airways, increase mucus production and swelling, and attract eosinophils to the lung.

These substances include:

  • PAF
  • Prostaglandins
  • Thromboxane

Macrophages can ultimately increase asthma symptoms.

Late Phase

The late phase of asthma occurs over the next few hours, as many of these cells make their way to the lungs, causing increased bronchoconstriction and inflammation, which makes it harder for you to breathe.

Neutrophils, eosinophils, and Th2 cells are especially believed to be a part of the late-phase response. These cells can be found in the sputum of people with asthma and may be associated with severe exacerbations.

Impact on Asthma Treatment

While there is no cure for asthma, treatment can control its symptoms and slow—if not entirely stop—its progression.

With the pathogenesis and pathophysiology of asthma in mind, healthcare providers can recommend strategies to either minimize or normalize the response, or prevent it from happening altogether. Given the variety of elements involved in these processes, your asthma management plan will very likely be multi-pronged.

Visit your healthcare provider regularly so they can monitor your respiratory health and alter your treatment plan over time, as needed.


Certain medications target specific cells and the processes they're involved in, which is why it's so important for healthcare provider

s to consider all that is happening in the body to cause asthma symptoms.

Some classes of medications used for treating asthma include:

  • Bronchodilators: A mainstay of treatment for any asthma type, these help relax the muscles of the airways. Short-acting bronchodilators, often called rescue inhalers, are used to end asthma attacks or to prevent exercise-induced bronchospasm. Long-acting bronchodilators are taken regularly to prevent attacks.
  • Mast cell stabilizers: These are medications for allergic asthma that reduce inflammation by preventing mast cells from releasing histamine and other inflammatory chemicals.
  • Leukotriene modifiers: These drugs prevent leukotrines from prompting bronchoconstriction and airway inflammation as part of the body's allergic response.
  • Antihistamines: Antihistamines are used to prevent the allergic responses that can lead to asthma attacks. Because histamines aren't the only chemicals involved in asthma, these drugs are typically taken with other asthma medications.


Asthma management isn't just about diligent use of your prescribed medications. Given the body's response to stimuli, it is also important to do what you can to prevent the cascade of events that occur after exposure by avoiding asthma triggers in the first place. The same goes for mitigating factors that can only worsen inflammation and bronchoconstriction.

This can include:

  • Getting vaccinated against the flu or pneumonia
  • Being mindful of potential exposures and altering your day-to-day to avoid them as much as possible (for example, staying indoors when pollen counts are high)
  • Making your home environment asthma-friendly (e.g., eradicating mold, using allergen-proof bedding)
  • Making lifestyle choices that improve lung function, including following a healthful diet, exercising, and not smoking

A Word From Verywell

The nitty-gritty about what makes asthma come about may ultimately seem most relevant to your healthcare provider. And to a large extent, that is true. That said, it hopefully gives you a better sense of what is happening in your body and why certain treatments and management approaches are working and why others are worth adding on and committing to.

18 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Castillo JR, Peters SP, Busse WW. Asthma exacerbations: Pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918-927. doi:10.1016/j.jaip.2017.05.001  

  2. Zhou-Suckow Z, Duerr J, Hagner M, Agrawal R, Mall MA. Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases. Cell Tissue Res. 2017;367(3):537-550. doi:10.1007/s00441-016-2562-z

  3. Yamauchi K, Inoue H. Airway remodeling in asthma and irreversible airflow limitation-ECM deposition in airway and possible therapy for remodeling. Allergol Int. 2007;56(4):321-9. doi:10.2332/allergolint.R-07-151

  4. Ferreira VL, Borba HH, Bonetti ADF, Leonart LP, Pontarolo R. Cytokines and interferons: Types and functionsAutoantibodies and Cytokines. 2019. doi:10.5772/intechopen.74550

  5. Yamauchi K, Ogasawara M. The role of histamine in the pathophysiology of asthma and the clinical efficacy of antihistamines in asthma therapy. Int J Mol Sci. 2019;20(7) doi:10.3390/ijms20071733

  6. Lee K, Lee SH, Kim TH. The biology of prostaglandins and their role as a target for allergic airway disease therapyInt J Mol Sci. 2020;21(5):1851. doi:10.3390/ijms21051851

  7. Al-Azzam N, Elsalem L. Leukotriene D4 role in allergic asthma pathogenesis from cellular and therapeutic perspectivesLife Sci. 2020;260:118452. doi:10.1016/j.lfs.2020.118452

  8. Ulambayar B, Yang EM, Cha HY, Shin YS, Park HS, Ye YM. Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational studyClin Transl Allergy. 2019;9:33. doi:10.1186/s13601-019-0275-6

  9. Siracusa MC, Kim BS, Spergel JM, Artis D. Basophils and allergic inflammationJ Allergy Clin Immunol. 2013;132(4):789-788. doi:10.1016/j.jaci.2013.07.046

  10. de Groot JC, ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era beginsERJ Open Res. 2015;1(1):00024-2015-. doi:10.1183/23120541.00024-2015

  11. Ray A, Kolls JK. Neutrophilic inflammation in asthma and association with disease severityTrends Immunol. 2017;38(12):942-954. doi:10.1016/

  12. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunityNat Rev Immunol. 2011;11(8):519-531. doi:10.1038/nri3024

  13. Rucker D, Dhamoon AS. Physiology, thromboxane A2. In: StatPearls. Treasure Island (FL): StatPearls Publishing.

  14. Fahy JV. Type 2 inflammation in asthma--present in most, absent in manyNat Rev Immunol. 2015;15(1):57-65. doi:10.1038/nri3786

  15. Quirt J, Hildebrand KJ, Mazza J, Noya F, Kim H. AsthmaAllergy Asthma Clin Immunol. 2018;14(Suppl 2):50. doi:10.1186/s13223-018-0279-0

  16. Price D, Fletcher M, Van der molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. doi:10.1038/npjpcrm.2014.9

  17. Finn DF, Walsh JJ. Twenty-first century mast cell stabilizersBr J Pharmacol. 2013;170(1):23-37. doi:10.1111/bph.12138

  18. Singh RK, Tandon R, Dastidar SG, Ray A. A review on leukotrienes and their receptors with reference to asthmaJ Asthma. 2013;50(9):922-931. doi:10.3109/02770903.2013.823447

Additional Reading

By Pat Bass, MD
Dr. Bass is a board-certified internist, pediatrician, and a Fellow of the American Academy of Pediatrics and the American College of Physicians.